0001192482-13-000219.txt : 20131211 0001192482-13-000219.hdr.sgml : 20131211 20131211181107 ACCESSION NUMBER: 0001192482-13-000219 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20131211 FILED AS OF DATE: 20131211 DATE AS OF CHANGE: 20131211 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TETRALOGIC PHARMACEUTICALS CORP CENTRAL INDEX KEY: 0001361248 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 343 PHOENIXVILLE PIKE CITY: MALVERN STATE: PA ZIP: 19355 BUSINESS PHONE: 610-889-9900 MAIL ADDRESS: STREET 1: 343 PHOENIXVILLE PIKE CITY: MALVERN STATE: PA ZIP: 19355 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Woody James N. CENTRAL INDEX KEY: 0001553355 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36208 FILM NUMBER: 131271979 MAIL ADDRESS: STREET 1: C/O ONCOMED PHARMACEUTICALS, INC. STREET 2: 800 CHESAPEAKE DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 3 1 edgar.xml PRIMARY DOCUMENT X0206 3 2013-12-11 0 0001361248 TETRALOGIC PHARMACEUTICALS CORP TLOG 0001553355 Woody James N. C/O TETRALOGIC PHARMACEUTICALS CORP 343 PHOENIXVILLE PIKE MALVERN PA 19355 1 0 0 0 Series B Convertible Preferred Stock Common Stock 354663 I Directly owned by LVP Life Science Ventures III, L.P Series B Convertible Preferred Stock Common Stock 17733 I Directly owned by LVP III Associates, L.P. Series B Convertible Preferred Stock Common Stock 8866 I Directly owned by LVP III Partners, L.P. Series C Convertible Preferred Stock Common Stock 227266 I Directly owned by LVP Life Sciences Ventures III, L.P. Series C Convertible Preferred Stock Common Stock 11363 I Directly owned by LVP III Associates, L.P. Series C Convertible Preferred Stock Common Stock 5681 I Directly owned by LVP Partners III, L.P. Common Stock Warrants .85 Common Stock 3475 I Directly owned by LVP Life Sciences Ventures III, L.P. Common Stock Warrants .85 Common Stock 174 I Directly owned by LVP III Associates, L.P. Common Stock Warrants .85 Common Stock 87 I Directly owned by LVP III Partners, L.P. Common Stock Warrants .85 Common Stock 4170 I Directly owned by LVP Life Sciences Ventures III, L.P. Common Stock Warrants .85 Common Stock 208 I Directly owned by LVP III Associates, L.P. Common Stock Warrants .85 Common Stock 104 I Directly owned by LVP III Partners, L.P. Convertible Notes Common Stock I Directly owned by LVP Life Science Ventures III, L.P. Convertible Notes Common Stock I Directly owned by LVP III Associates, L.P. Convertible Notes Common Stock I Directly owned by LVP III Partners, L.P. Series C Warrants 6.4022 Common Stock I Directly owned by LVP Life Science Ventures III, L.P. Series C Warrants 6.4022 Common Stock I Directly owned by LVP III Associates, L.P. Series C Warrants 6.4022 Common Stock I Directly owned by LVP III Partners, L.P. The Series B Convertible Preferred Stock will be automatically converted into Common Stock without payment of further consideration upon the closing of the Issuer's initial public offering and has no expiration date. The Series C Convertible Preferred Stock will be automatically converted into Common Stock without payment of further consideration upon the closing of the Issuer's initial public offering and has no expiration date. The warrants are immediately exercisable. The warrants expire on the later of 11/25/2019 or five years after the consummation of the Company's initial public offering. The warrants are immediately exercisable. The warrants expire on the later of 03/10/2020 or five years after the consummation of the Company's initial public offering. The Convertible Notes will be automatically converted into Common Stock without payment of further consideration upon the closing of the Issuer's initial public offering and have no expiration date. Warrants will be automatically exercised immediately prior to the closing of the Issuer's initial public offering. Warrants are exercisable for a number of shares of common stock equal to the warrant amount divided by the exercise price and will be net exercised at the initial public offering price. The reported securities are owned directly by each of LVP Life Science Ventures III, L.P. ("LVP III"), LVP III Associates, L.P. ("Associates"), and LVP III Partners, L.P. ("Partners"). LVP GP III, LLC ("GP III") is the general partner of LVP III, Associates, and Partners. The reporting person, a member of GP III, shares voting and investment power with respect to these shares but disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein. James N. Woody 2013-12-11